Laser photocoagulation superior to new drug for diabetic eye condition - NICE
This article was originally published in Clinica
Laser photocoagulation should be retained as the technology of choice for the treatment of diabetic macular oedema (DMO), instead of Novartis’ Lucentis (ranibizumab), according to draft guidelines by the UK’s National Institute for Health and Clinical Excellence (NICE).
You may also be interested in...
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.